Below is the excerpt from the announcement dated Feb 2017. They have exceeded the outcomes of the supplemental tests with excellent trial results. Can’t wait until they have their meeting with BSI and the oversight committee and this is all sorted.
“Based on information received from BSI, the Company is pleased to advise that CE Certification for the pancreatic cancer indication will now be granted subject to the following conditions:
•Provision of supplemental data from 20 locally advanced pancreatic cancer patients supporting the existing safety and clinical performance data already reviewed,”
OSL Price at posting:
5.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)